Lorbriqua 25mg Tablet

Prezentare produs

About Lorbriqua

Lorbriqua is a medication containing the active ingredient lorlatinib, classified as Kinase Inhibitor. Lorlatinib, sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer medication used for the treatment of non-small cell lung cancer.

Key Benefits & Uses

• Used for: 1 INDICATIONS AND USAGE LORBRENA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors.
• Use only as directed on the product label or by a healthcare professional.
• Follow the authorised product information for dosing and duration of use.

Active Ingredient & Action

lorlatinib, the active ingredient in Lorbriqua, belongs to the Kinase Inhibitor class. 1 INDICATIONS AND USAGE LORBRENA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. Inactive ingredients: not listed in source data.

Important Notes

Always read and follow the label instructions carefully before taking Lorbriqua. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use Lorbriqua for extended periods without medical advice.